NH SPAC 2 Asset Resilience Ratio
NH SPAC 2 asset resilience ratio. NH SPAC 2 (206640) has an Asset Resilience Ratio of 6.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NH SPAC 2 (206640) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NH SPAC 2 (2015–2025)
Asset resilience ratio of NH SPAC 2 from 2015 to 2025. This chart shows how NH SPAC 2's Asset Resilience Ratio has changed over time. Read NH SPAC 2 balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NH SPAC 2's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NH SPAC 2 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩18.17 Billion | 6.45% |
| Total Liquid Assets | ₩18.17 Billion | 6.45% |
Asset Resilience Insights
- Limited Liquidity: NH SPAC 2 maintains only 6.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NH SPAC 2 Industry Peers by Asset Resilience Ratio
Compare NH SPAC 2's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
NH SPAC 2 Asset Resilience Ratio by Year (2015–2025)
NH SPAC 2 asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for NH SPAC 2.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.45% | ₩18.17 Billion ≈ $12.31 Million |
₩281.63 Billion ≈ $190.86 Million |
-17.78pp |
| 2024-12-31 | 24.23% | ₩61.71 Billion ≈ $41.82 Million |
₩254.67 Billion ≈ $172.59 Million |
-9.20pp |
| 2023-12-31 | 33.43% | ₩76.20 Billion ≈ $51.64 Million |
₩227.90 Billion ≈ $154.45 Million |
+2.54pp |
| 2022-12-31 | 30.89% | ₩60.44 Billion ≈ $40.96 Million |
₩195.66 Billion ≈ $132.59 Million |
-4.72pp |
| 2021-12-31 | 35.61% | ₩68.45 Billion ≈ $46.39 Million |
₩192.24 Billion ≈ $130.28 Million |
-0.08pp |
| 2020-12-31 | 35.68% | ₩58.34 Billion ≈ $39.53 Million |
₩163.47 Billion ≈ $110.78 Million |
+14.27pp |
| 2019-12-31 | 21.42% | ₩21.69 Billion ≈ $14.70 Million |
₩101.26 Billion ≈ $68.62 Million |
-3.51pp |
| 2018-12-31 | 24.93% | ₩25.79 Billion ≈ $17.47 Million |
₩103.44 Billion ≈ $70.10 Million |
+1.63pp |
| 2017-12-31 | 23.30% | ₩25.20 Billion ≈ $17.08 Million |
₩108.17 Billion ≈ $73.30 Million |
+8.25pp |
| 2016-12-31 | 15.05% | ₩13.67 Billion ≈ $9.26 Million |
₩90.79 Billion ≈ $61.53 Million |
+5.49pp |
| 2015-12-31 | 9.56% | ₩6.86 Billion ≈ $4.65 Million |
₩71.71 Billion ≈ $48.59 Million |
-- |
About NH SPAC 2
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more